Welcome

Latest Press Release

CollaGenex Pharmaceuticals Announces Expiration of the Hart-Scott-Rodino Waiting Period for Merger with Galderma Pharma S.A.

Current Stock Quote

Current Stock Quote
Research Drivern, Dermatology Focused
Clinical Research Update

CollaGenex Pharmaceuticals Announces Results of Phase 4 Clinical Study Showing Oracea Equally Effective as 100 mg Doxycycline in Treatment of Rosacea







© 2008 CollaGenex Pharmaceuticals Inc. All Rights Reserved.

This Web site contains forward-looking statements within the meaning of Section 21E of the Securities and Exchange Act of 1934, as amended. Investors are cautioned that forward-looking statements involve risks and uncertainties, which may affect the company's business and prospects.